AI app to help manage atopic dermatitis
Construction and Evaluation of an Artificial Intelligence Assistant Decision-making System Focused on the Treat to Target Framework and Full Process Management for Atopic Dermatitis
This study is testing a new AI app designed to help people with atopic dermatitis manage their skin condition better by using images to track and evaluate their symptoms.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 232 (estimated) |
| Ages | 1 Year to 75 Years |
| Sex | All |
| Sponsor | West China Hospital Academic / other |
| Locations | 1 site (Chengdu, Sichuan) |
| Trial ID | NCT06362629 on ClinicalTrials.gov |
What this trial studies
This project aims to develop an Artificial Intelligence assistant decision-making system (AIADMS) to enhance the management of atopic dermatitis (AD) using a Treat to Target (T2T) strategy. The study will utilize a dataset of over 10,000 clinical images of AD to train the AI system for automatic detection and evaluation of skin lesions. Dermatologists will label clinical signs and severity of the lesions, which will be used to improve patient adherence to treatment and optimize clinical outcomes. Participants will be recruited from the West China Hospital of Sichuan University, where informed consent will be obtained prior to involvement.
Who should consider this trial
Good fit: Ideal candidates for this study are individuals aged 1 to 75 years diagnosed with atopic dermatitis who can communicate in Chinese and are familiar with smartphone or tablet usage.
Not a fit: Patients with serious coexisting diseases, mental illness, or communication difficulties may not benefit from this study.
Why it matters
Potential benefit: If successful, this AI app could significantly improve disease management and quality of life for patients with atopic dermatitis.
How similar studies have performed: While the use of AI in dermatology is gaining traction, this specific application of AI for atopic dermatitis management is relatively novel and has not been extensively tested in prior studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Diagnosed with AD, aged 1\~75 years; be able to communicate in Chinese; with basic reading and writing skills; participants or the guardian have smartphones or pads and are familiar with the use skills. Exclusion Criteria: * Mental illness; personality disorder; language barrier; hearing impairment; communication difficulties; with serious coexisting diseases, such as cardiopulmonary insufficiency, liver dysfunction, renal dysfunction, blood system diseases, tumors, or other diseases; other situations that not suitable for participating in clinical trial.
Where this trial is running
Chengdu, Sichuan
- West China Hospital, Sichuan University — Chengdu, Sichuan, China (Recruiting)
Study contacts
- Principal investigator: Jingyi Li, M.D. — West China Hospital
- Study coordinator: Jingyi Li, M.D.
- Email: jingyili@wchscu.cn
- Phone: +8618980605704
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.